Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease.

Washington

District of Columbia

United States

FDA approves first once-weekly drug treatment regimen for hemophilia

Ad Fontes Media

All Sides

Media Bias/Fact Check

News World Communications

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.

MarketWatch

Murdoch family

Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient. Article Attribution | Read More at Article Source The post Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment appeared first on RocketNews.

RocketNews

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

ajmc.com

FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B

Marstacimab-hncq is the first non-factor and once-weekly treatment available for patients with hemophilia B and promises to reduce the burden of care.

FDA approves first once-weekly drug treatment regimen for hemophilia

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics